New Four-Drug cocktail aims to wipe out Hard-to-Treat myeloma

NCT ID NCT07709884

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests a combination of four drugs—sotoclax, carfilzomib, lenalidomide, and dexamethasone (called SonKRd)—in people newly diagnosed with multiple myeloma that has a specific genetic change called t(11;14). Participants must be healthy enough for a stem cell transplant. The main goal is to see how many patients achieve minimal residual disease (MRD) negativity, meaning no cancer cells can be detected after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of four drugs: sotoclax, carfilzomib, lenalidomide, and dexamethasone
What this could lead to: If successful, this regimen could offer a highly effective first-line treatment for people with this specific genetic subtype of multiple myeloma, potentially leading to deeper and longer-lasting remissions.
What could go wrong: This is a small, single-center study with only 20 participants, so results may not apply to everyone. The combination also carries risks of side effects from the drugs, including infections and organ stress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARFILZOMIB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Sotos syndrome T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARFILZOMIB NEWLY DIAGNOSED MULTIPLE MYELOMA SOTOCLAX T(11;14)

Contacts and locations

Locations

First Affiliated Hospital, Soochow University

Suzhou, Jiangsu, 215000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.